Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
Last trade$1.02
Day change-$0.065 (-6.02%)
Day range$0.986 – $1.08
Volume2,811,879
Market cap$104M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$104.03M
Price / earnings
—
Price / book
0.59×
Price / sales
—
EV / sales
—
EV / EBITDA
0.82×
Profitability
Earnings per share
-$1.27
Return on assets
-62.8%
Return on equity
-68.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.29×
Quick ratio
11.29×
Cash ratio
11.06×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$22.35M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ZURA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$9.28M
$8.62M
$10.75M
$7.46M
$7.57M
$9.36M
$8.78M
$6.49M
Research and development
$19.49M
$20.71M
$14.75M
$10.96M
$11.95M
$8.7M
$10.47M
$9.24M
Total operating expenses
$28.77M
$29.32M
$25.5M
$18.41M
$19.52M
$18.06M
$19.25M
$15.73M
Operating income
-$28.77M
-$29.32M
-$25.5M
-$18.41M
-$19.52M
-$18.06M
-$19.25M
-$15.73M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$27.05M
-$26.39M
-$24.22M
-$17.18M
-$18.04M
-$15.99M
-$17.44M
-$13.63M
Income taxes
-$1.22M
-$81K
$0
$0
$0
$0
$0
$0
Net income
-$25.83M
-$26.3M
-$24.22M
-$17.18M
-$18.04M
-$15.99M
-$17.44M
-$13.63M
Net income attributable to common shareholders
-$25.83M
-$26.3M
-$24.22M
-$45.88M
-$20.04M
-$15.99M
-$17.44M
-$9.05M
EBITDA
-$28.77M
-$29.34M
-$25.48M
-$18.4M
-$19.52M
-$18.07M
-$19.25M
-$15.73M
Basic earnings per share
-$0.20
-$0.21
-$0.22
-$0.48
-$0.21
-$0.17
-$0.19
-$0.10
Diluted earnings per share
-$0.20
-$0.21
-$0.22
-$0.48
-$0.21
-$0.17
-$0.19
-$0.10
Recent news
Company coverage with links to the original publishers.
JATT II Acquisition Corp, a blank check company focused on healthcare and biotechnology, successfully closed its $60 million IPO on April 20, 2026, offering 6 million shares at $10 per share on NASDAQ under ticker 'JATT'. The company, led by Dr. Someit Sidhu and sponsored by JATT Ventures II L.P., intends to pursue business combinations in healthcare and life sciences sectors with emphasis on data-driven therapeutic discovery approaches.
A comprehensive analysis reveals a robust pipeline for hidradenitis suppurativa treatment, with 24+ companies developing 26+ therapies, focusing on innovative biologic and targeted approaches like IL-17 and JAK inhibitors to address significant unmet clinical needs.
Multiple health care and biotech stocks experienced significant price movements, with some stocks seeing substantial gains while others faced sharp declines during Monday's trading session.
The consensus price target hints at a 235.2% upside potential for Zura Bio Limited (ZURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Zura Bio Limited (ZURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.